https://www.gsk-china.com/zh-cn/ 2026-08-24T17:16:41.37Z https://www.gsk-china.com/zh-cn/%E6%90%9C%E7%B4%A2/ 2025-07-10T16:34:52.853Z https://www.gsk-china.com/zh-cn/error-404/ 2026-01-26T19:30:54.093Z https://www.gsk-china.com/zh-cn/sitemap/ 2025-07-10T10:40:53.88Z https://www.gsk-china.com/zh-cn/terms-of-use/ 2025-07-16T13:09:05.693Z https://www.gsk-china.com/zh-cn/vaccine-publicity/ 2025-07-10T10:43:27.457Z https://www.gsk-china.com/zh-cn/vaccine-publicity/engerix/ 2025-07-10T10:45:20.643Z https://www.gsk-china.com/zh-cn/vaccine-publicity/shingrix/ 2026-03-11T16:23:48.823Z https://www.gsk-china.com/zh-cn/vaccine-publicity/cervarix/ 2025-07-01T14:45:22.623Z https://www.gsk-china.com/zh-cn/vaccine-publicity/engerix-pdf/ 2025-08-31T16:11:17.627Z https://www.gsk-china.com/zh-cn/vaccine-publicity/shingrix-pdf/ 2026-09-08T10:44:44.387Z https://www.gsk-china.com/zh-cn/vaccine-publicity/cervarix-pdf/ 2026-01-12T16:47:00.28Z https://www.gsk-china.com/zh-cn/vaccine-publicity/batch-issuance/ 2026-05-19T11:02:20.667Z https://www.gsk-china.com/zh-cn/vaccine-publicity/summary-of-quality-publicity-information/ 2025-12-25T13:53:02.24Z https://www.gsk-china.com/zh-cn/vaccine-publicity/insurance-of-quality-compulsory-liability-insurance/ 2025-07-01T14:45:17.413Z https://www.gsk-china.com/zh-cn/cookie-policy/ 2025-07-16T13:09:09.453Z https://www.gsk-china.com/zh-cn/accessibility-legal/ 2025-07-16T13:09:12.96Z https://www.gsk-china.com/zh-cn/contact-us/ 2025-07-16T13:09:00.903Z https://www.gsk-china.com/zh-cn/company/ 2026-03-11T13:19:53.01Z https://www.gsk-china.com/zh-cn/company/purpose-and-strategy/ 2026-02-27T17:26:11.807Z https://www.gsk-china.com/zh-cn/company/purpose-and-strategy/hiv/ 2025-07-01T14:45:13.583Z https://www.gsk-china.com/zh-cn/company/purpose-and-strategy/infectious-diseases/ 2025-07-01T14:45:12.79Z https://www.gsk-china.com/zh-cn/company/purpose-and-strategy/oncology/ 2025-07-01T14:45:12.09Z https://www.gsk-china.com/zh-cn/company/purpose-and-strategy/respiratory/ 2025-07-01T14:45:11.047Z https://www.gsk-china.com/zh-cn/company/purpose-and-strategy/specialty-medicines/ 2025-07-01T14:45:10.217Z https://www.gsk-china.com/zh-cn/company/purpose-and-strategy/vaccines/ 2025-07-01T14:45:09.51Z https://www.gsk-china.com/zh-cn/company/purpose-and-strategy/immunology/ 2025-07-01T14:45:08.603Z https://www.gsk-china.com/zh-cn/company/at-a-glance/ 2025-07-16T13:41:26.587Z https://www.gsk-china.com/zh-cn/company/company-policies-and-standards/ 2026-03-13T16:36:38.743Z https://www.gsk-china.com/zh-cn/company/wechat/ 2025-07-16T13:34:02.54Z https://www.gsk-china.com/zh-cn/innovation/ 2026-03-11T13:28:46.57Z https://www.gsk-china.com/zh-cn/innovation/therapy-areas/ 2026-02-27T17:37:47.043Z https://www.gsk-china.com/zh-cn/innovation/trials/ 2026-02-28T12:54:19.003Z https://www.gsk-china.com/zh-cn/products/ 2026-03-11T15:38:25.913Z https://www.gsk-china.com/zh-cn/products/product-areas/ 2025-07-01T14:44:40.503Z https://www.gsk-china.com/zh-cn/products/product-list/ 2025-07-01T14:44:38.73Z https://www.gsk-china.com/zh-cn/responsibility/ 2026-03-11T15:48:57.387Z https://www.gsk-china.com/zh-cn/responsibility/inclusion/ 2026-04-29T16:03:15.513Z https://www.gsk-china.com/zh-cn/responsibility/ethical-standards/ 2026-09-22T11:25:49.48Z https://www.gsk-china.com/zh-cn/responsibility/ethical-standards/engaging-with-healthcare-professionals/ 2025-07-01T14:44:26.54Z https://www.gsk-china.com/zh-cn/responsibility/ethical-standards/disclosure-of-payments-made-to-hcps/ 2025-07-16T13:34:15.493Z https://www.gsk-china.com/zh-cn/responsibility/avodart-announcement/ 2025-07-01T14:44:10.68Z https://www.gsk-china.com/zh-cn/media/ 2026-02-28T17:39:01.743Z https://www.gsk-china.com/zh-cn/media/press-releases/ 2025-07-16T15:10:24.807Z https://www.gsk-china.com/zh-cn/media/press-releases/hiv-dovato-launch-in-china/ 2025-07-16T15:09:30.08Z https://www.gsk-china.com/zh-cn/media/press-releases/hiv-dovato-approval-in-china/ 2025-07-16T15:09:29.78Z https://www.gsk-china.com/zh-cn/media/press-releases/lamictal-new-indication-bipolar-approval/ 2025-07-16T15:09:29.557Z https://www.gsk-china.com/zh-cn/media/press-releases/viiv-healthcare-tivicay/ 2025-07-16T15:09:29.3Z https://www.gsk-china.com/zh-cn/media/press-releases/viiv-healthcare-dovato/ 2025-07-16T15:09:29.083Z https://www.gsk-china.com/zh-cn/media/press-releases/benlysta-new-indication-for-pedi/ 2025-07-16T15:09:31.54Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-sets-new-goal-for-environmental-objective/ 2025-07-16T15:09:31.22Z https://www.gsk-china.com/zh-cn/media/press-releases/shingrix-launch/ 2025-07-16T15:09:31Z https://www.gsk-china.com/zh-cn/media/press-releases/clover/ 2025-07-16T15:09:30.783Z https://www.gsk-china.com/zh-cn/media/press-releases/viiv-healthcare-cabotegravir/ 2025-07-16T15:09:30.553Z https://www.gsk-china.com/zh-cn/media/press-releases/sanofi-gsk/ 2025-07-16T15:09:30.327Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-innovax-covid-2019/ 2025-07-16T15:09:32.823Z https://www.gsk-china.com/zh-cn/media/press-releases/trelegy-ali-health/ 2025-07-16T15:09:32.507Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-clover/ 2025-07-16T15:09:32.287Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-cepi/ 2025-07-16T15:09:31.973Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-china-donated-rmb-2million/ 2025-07-16T15:09:31.757Z https://www.gsk-china.com/zh-cn/media/press-releases/fda-approval-for-benlysta/ 2025-07-16T15:09:28.813Z https://www.gsk-china.com/zh-cn/media/press-releases/sierra-oncology/ 2025-07-16T15:09:33.08Z https://www.gsk-china.com/zh-cn/media/press-releases/bepirovirsens-clinical-trial-data/ 2025-07-16T15:09:33.303Z https://www.gsk-china.com/zh-cn/media/press-releases/1-billion-investment-in-rd-in-next-decade/ 2025-07-16T15:09:33.527Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-sanofi-announced/ 2025-07-16T15:09:33.773Z https://www.gsk-china.com/zh-cn/media/press-releases/egpa-launch-in-china/ 2025-07-16T15:09:33.987Z https://www.gsk-china.com/zh-cn/media/press-releases/affinivax/ 2025-07-16T15:09:34.21Z https://www.gsk-china.com/zh-cn/media/press-releases/cervarix-two-doses/ 2025-07-16T15:09:34.52Z https://www.gsk-china.com/zh-cn/media/press-releases/blenrep-in-boao/ 2025-07-16T15:09:34.783Z https://www.gsk-china.com/zh-cn/media/press-releases/dovato-new-indication/ 2025-07-16T15:09:35.043Z https://www.gsk-china.com/zh-cn/media/press-releases/covid-10-increased-risk-of-shingles/ 2025-07-16T15:09:35.277Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-sanofi-submit-application/ 2025-07-16T15:09:35.5Z https://www.gsk-china.com/zh-cn/media/press-releases/benlysta-approval-for-ln-in-china/ 2025-07-16T15:09:35.723Z https://www.gsk-china.com/zh-cn/media/press-releases/hiv-dovato-first-prescription-in-china/ 2025-07-16T15:09:36.037Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-medicago-1/ 2025-07-16T15:09:36.297Z https://www.gsk-china.com/zh-cn/media/press-releases/sotrovimab/ 2025-07-16T15:09:36.597Z https://www.gsk-china.com/zh-cn/media/press-releases/2021-nrdl-benlysta/ 2025-07-16T15:09:36.813Z https://www.gsk-china.com/zh-cn/media/press-releases/2021-nrdl-hiv-dovato/ 2025-07-16T15:09:37.1Z https://www.gsk-china.com/zh-cn/media/press-releases/egpa-nucala-approval-in-china/ 2025-07-16T15:09:37.333Z https://www.gsk-china.com/zh-cn/media/press-releases/2021-gsk-china-ciie/ 2025-07-16T15:09:37.72Z https://www.gsk-china.com/zh-cn/media/press-releases/curevac-gsk/ 2025-07-16T15:09:37.963Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-vir-biotechnology/ 2025-07-16T15:09:38.213Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-medicago/ 2025-07-16T15:09:38.443Z https://www.gsk-china.com/zh-cn/media/press-releases/shingrix-provide-at-least-10-years-of-protection/ 2025-07-16T15:09:38.66Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-s-older-adult-rsv-vaccine-candidate/ 2025-07-16T15:09:38.867Z https://www.gsk-china.com/zh-cn/media/press-releases/positive-data-for-bepirovirsen-from-b-clear-phase/ 2025-07-16T15:09:39.21Z https://www.gsk-china.com/zh-cn/media/press-releases/dovato-stable-switch-nrdl/ 2025-07-16T15:09:39.443Z https://www.gsk-china.com/zh-cn/media/press-releases/nucala-nrdl/ 2025-07-16T15:09:39.68Z https://www.gsk-china.com/zh-cn/media/press-releases/hiv-nrdl/ 2025-07-16T15:09:39.913Z https://www.gsk-china.com/zh-cn/media/press-releases/nucala-sea-nda-china/ 2025-07-16T15:09:40.127Z https://www.gsk-china.com/zh-cn/media/press-releases/arexvy-us-fda-approval/ 2025-07-16T15:09:40.447Z https://www.gsk-china.com/zh-cn/media/press-releases/sle-mini-movie/ 2025-07-16T15:09:40.7Z https://www.gsk-china.com/zh-cn/media/press-releases/nucala-sea-phase-3/ 2025-07-16T15:09:40.997Z https://www.gsk-china.com/zh-cn/media/press-releases/launch-of-lupus-centre/ 2025-07-16T15:09:41.267Z https://www.gsk-china.com/zh-cn/media/press-releases/hivccb-launch/ 2025-07-16T15:09:51.427Z https://www.gsk-china.com/zh-cn/media/press-releases/076-study-results/ 2025-07-16T15:09:51.663Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-and-zhifei/ 2025-07-16T15:09:51.997Z https://www.gsk-china.com/zh-cn/media/press-releases/hiv-vplusr/ 2025-07-16T15:09:52.28Z https://www.gsk-china.com/zh-cn/media/press-releases/2023ciie/ 2025-07-16T15:09:52.543Z https://www.gsk-china.com/zh-cn/media/press-releases/nucala-approved-in-china/ 2025-07-16T15:09:55.337Z https://www.gsk-china.com/zh-cn/media/press-releases/shingrix-new-long-term-data/ 2025-07-16T15:09:55.57Z https://www.gsk-china.com/zh-cn/media/press-releases/hiv-prep-approval/ 2025-07-16T15:09:55.843Z https://www.gsk-china.com/zh-cn/media/press-releases/statement/ 2025-07-16T15:09:52.783Z https://www.gsk-china.com/zh-cn/media/press-releases/blenrep-dreamm-7/ 2025-07-16T15:09:53.017Z https://www.gsk-china.com/zh-cn/media/press-releases/data-for-arexvy/ 2025-07-16T15:09:53.347Z https://www.gsk-china.com/zh-cn/media/press-releases/b-united-ind-approval/ 2025-07-16T15:09:53.637Z https://www.gsk-china.com/zh-cn/media/press-releases/blenrep-nda/ 2025-07-16T15:09:53.88Z https://www.gsk-china.com/zh-cn/media/press-releases/nucala-crswnp/ 2025-07-16T15:09:54.117Z https://www.gsk-china.com/zh-cn/media/press-releases/apretude-launch/ 2025-07-16T15:09:54.35Z https://www.gsk-china.com/zh-cn/media/press-releases/nucala-copd-filling-acceptance/ 2025-07-16T15:09:54.673Z https://www.gsk-china.com/zh-cn/media/press-releases/nucala-copd-fda-approval/ 2025-07-16T15:09:55.03Z https://www.gsk-china.com/zh-cn/media/press-releases/blenrep-combination-eu-fda-approval/ 2025-08-31T15:56:38.997Z https://www.gsk-china.com/zh-cn/media/press-releases/bepirovirsen-phase-iii-results/ 2026-01-12T18:21:28.983Z https://www.gsk-china.com/zh-cn/media/press-releases/trelegy-asthma-approved-in-china/ 2026-01-23T19:13:05.427Z https://www.gsk-china.com/zh-cn/media/press-releases/nucala-copd-china-approval/ 2026-04-16T18:12:00.497Z https://www.gsk-china.com/zh-cn/media/press-releases/rsv-china-phase-iii-positive-data/ 2026-01-30T16:02:26.387Z https://www.gsk-china.com/zh-cn/media/press-releases/rsv-accepted-by-nmpa/ 2026-02-11T14:19:26.117Z https://www.gsk-china.com/zh-cn/media/press-releases/%E6%98%93%E9%80%82%E6%9D%A5-%E5%BE%B7%E8%8E%AB%E5%A5%87%E5%8D%95%E6%8A%97-%E5%9C%A8%E4%B8%AD%E5%9B%BD%E8%8E%B7%E6%89%B9%E7%94%A8%E4%BA%8E%E6%88%90%E4%BA%BA%E5%92%8C12%E5%B2%81%E5%8F%8A%E4%BB%A5%E4%B8%8A%E9%9D%92%E5%B0%91%E5%B9%B4%E9%87%8D%E5%BA%A6%E5%97%9C%E9%85%B8%E6%80%A7%E7%B2%92%E7%BB%86%E8%83%9E%E6%80%A7%E5%93%AE%E5%96%98%E7%9A%84%E7%BB%B4%E6%8C%81%E6%B2%BB%E7%96%97/ 2026-04-16T18:05:31.993Z https://www.gsk-china.com/zh-cn/media/press-releases/%E6%98%93%E9%80%82%E6%9D%A5-%E5%BE%B7%E8%8E%AB%E5%A5%87%E5%8D%95%E6%8A%97-%E5%9C%A8%E4%B8%AD%E5%9B%BD%E8%8E%B7%E6%89%B9%E7%94%A8%E4%BA%8E%E6%B2%BB%E7%96%97%E6%85%A2%E6%80%A7%E9%BC%BB%E7%AA%A6%E7%82%8E%E4%BC%B4%E9%BC%BB%E6%81%AF%E8%82%89%E6%88%90%E4%BA%BA%E6%82%A3%E8%80%85/ 2026-04-16T17:57:48.91Z https://www.gsk-china.com/zh-cn/media/press-releases/%E5%80%8D%E4%B9%90%E9%94%90-%E6%B3%A8%E5%B0%84%E7%94%A8%E7%8E%9B%E8%B4%9D%E5%85%B0%E5%A6%A5%E5%8D%95%E6%8A%97-%E8%8E%B7%E6%89%B9%E7%94%A8%E4%BA%8E%E6%B2%BB%E7%96%97%E4%BA%8C%E7%BA%BF%E5%8F%8A%E4%BB%A5%E4%B8%8A%E5%A4%9A%E5%8F%91%E6%80%A7%E9%AA%A8%E9%AB%93%E7%98%A4%E6%88%90%E5%B9%B4%E6%82%A3%E8%80%85/ 2026-04-20T15:27:06.403Z https://www.gsk-china.com/zh-cn/media/press-releases/sbp-group-collaboration/ 2026-05-11T14:50:51.333Z https://www.gsk-china.com/zh-cn/media/press-releases/bepi-phase-iii-read-out/ 2026-05-28T18:07:41.497Z https://www.gsk-china.com/zh-cn/media/press-releases/nucala-hes-approval/ 2026-07-06T10:34:28.297Z https://www.gsk-china.com/zh-cn/media/press-releases/gsk-and-sbp-group-deepen-strategic-collaboration/ 2026-07-08T12:04:32.527Z https://www.gsk-china.com/zh-cn/media/media-contacts/ 2025-07-01T14:38:14.567Z https://www.gsk-china.com/zh-cn/careers/ 2026-01-07T11:25:14.12Z https://www.gsk-china.com/zh-cn/careers/life-at-gsk/ 2026-02-28T17:53:53.237Z https://www.gsk-china.com/zh-cn/careers/experienced-professionals/ 2025-07-01T14:38:11.79Z https://www.gsk-china.com/zh-cn/careers/early-talent/ 2025-07-01T14:38:11.28Z https://www.gsk-china.com/zh-cn/market-website-selector/ 2025-07-08T15:01:31.637Z https://www.gsk-china.com/zh-cn/grant-portal/ 2025-12-22T17:48:35.11Z https://www.gsk-china.com/zh-cn/digital-sustainability/ 2026-08-24T17:11:16.963Z